

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/082893 A3

(51) International Patent Classification⁷: **A61K 31/585**,
A61P 9/02, 9/04, 11/06, 21/00, 21/04, 25/08, 25/16, 25/28,
27/00

(21) International Application Number:
PCT/GB2003/001380

(22) International Filing Date: 27 March 2003 (27.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P020101170 27 March 2002 (27.03.2002) AR
60/368,178 28 March 2002 (28.03.2002) US
PCT/GB02/01578 28 March 2002 (28.03.2002) GB

(71) Applicant (for all designated States except US): **PHY-
TOPHARM PLC** [GB/GB]; Corpus Christi House, 9 West
Street, Godmanchester, Cambridgeshire PE29 2HY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REES, Daryl**
[GB/GB]; Phytopharm plc, Corpus Christi House, 9, West
Street, Godmanchester, Cambridgeshire PE29 2HY (GB).
GUNNING, Phil [GB/GB]; Phytopharm plc, Corpus
Christi House, 9, West Street, Godmanchester, Cam-
bridgeshire PE29 2HY (GB). **ORSI, Antonia** [GB/GB];
Phytopharm plc, Corpus Christi House, 9, West Street,
Godmanchester, Cambridgeshire PE29 2HY (GB). **XIA,
Zongqin** [CN/CN]; Flat 403, Block 8, 1, Jian-De Road,
Shanghai 200025 (CN). **HU, Yaer** [CN/CN]; Flat 1209,
Block 1, Lane 357, Ma-Dang Road, Shanghai 200025
(CN).

(74) Agent: **BROWN, David, Leslie**; Haseltine Lake, Imperial
House, 15-19 Kingsway, London WC2B 6UD (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
15 April 2004

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 01/2004 of 31 December 2003, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THERAPUTIC METHODS AND USES OF SAPOGENINS AND THEIR DERIVATIVES

(57) Abstract: The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and deriva-
tives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neu-
rodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.

WO 2003/082893 A3

INTERNATIONAL SEARCH REPORT

PCT/GB 1380

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/585 A61P9/02 A61P9/04 A61P11/06 A61P21/00
A61P21/04 A61P25/08 A61P25/16 A61P25/28 A61P27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, SCISEARCH, BIOSIS, MEDLINE, EMBASE, WPI Data, EPO-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 024 146 A (INST OF RADIATION MEDICINE ACA) 2 August 2000 (2000-08-02) page 19, line 11 - line 12 page 33, line 46 -page 34, line 27 claims 1,3-20	1-7
X	WO 01 49703 A (HU YAER ;XIA ZONGQIN (CN); GUNNING PHIL (GB); HANSON JIM (GB); PHY) 12 July 2001 (2001-07-12) page 1, line 1 - line 22 page 7, line 11 -page 15, line 4 page 15, line 6 -page 16, line 24 page 22, line 32 - line 34 page 23, line 3 - line 35 claims 1-20,22,26,28,29	1-8

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 February 2004

Date of mailing of the international search report

16. 02. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M

INTERNATIONAL SEARCH REPORT

PCT/GB 1380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99 48507 A (HU YAER ;XIA ZONGQIN (CN); BROSTOFF JONATHAN (GB); RUBIN IAN (GB);) 30 September 1999 (1999-09-30) cited in the application page 1, line 5 - line 24 page 7, line 6 -page 8, line 4 page 9, line 5 - line 13 page 10, line 4 - line 11 page 15, line 9 -page 16, line 3 page 23, line 23 -page 24, line 8 claims 1-32</p> <p>---</p>	1-8
X	<p>WO 01 23406 A (HU YAER ;XIA ZONGQIN (CN); GUNNING PHIL (GB); HANSON JIM (GB); PHY) 5 April 2001 (2001-04-05) cited in the application page 1, line 4 - line 33 page 6, line 17 -page 9, line 17 page 13, line 4 - line 23 page 13, line 28 - line 30 page 15 -page 19; table 1 claims 1-15</p> <p>---</p>	1-8
X	<p>WO 01 23408 A (HU YAER ;XIA ZONGQIN (CN); GUNNING PHIL (GB); HANSON JIM (GB); PHY) 5 April 2001 (2001-04-05) cited in the application page 1, line 4 - line 22 page 6, line 16 -page 9, line 17 page 12, line 16 - line 24 page 13, line 16 -page 14, line 27 claims 1-13</p> <p>---</p>	1-8
X	<p>DE 43 03 214 A (MARKS WOLFGANG) 11 August 1994 (1994-08-11) cited in the application page 6, line 15 - line 26 page 7, line 10 - line 15 claims 1-3,7,14</p> <p>---</p>	1-8
X	<p>SUN, HUI ET AL: "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease" JOURNAL OF BIOLOGICAL CHEMISTRY (1999), 274(12), 8269-8281 , XP001165795 figures 2,3,9,10 page 8280, column 2, paragraph 3</p> <p>---</p>	1-3,5,8
X	<p>US 4 680 289 A (APPLEZWEIG NORMAN) 14 July 1987 (1987-07-14) tables I,II claims 16,18,19</p> <p>---</p>	5
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

PCT/GB 1380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 199343 Derwent Publications Ltd., London, GB; Class B04, AN 1993-339641 XP002157713 & JP 05 246866 A (KATO K), 24 September 1993 (1993-09-24) abstract</p> <p>---</p>	1-8
X	<p>WO 01 23407 A (HU YAER ;XIA ZONGQIN (CN); GUNNING PHIL (GB); HANSON JIM (GB); PHY) 5 April 2001 (2001-04-05) page 6, line 20 -page 8, line 32 claims 1-5,8,14</p> <p>---</p>	1,2,5-8
X	<p>PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05, 3 May 2002 (2002-05-03) & JP 2002 030096 A (KYORIN PHARMACEUT CO LTD), 29 January 2002 (2002-01-29) abstract</p> <p>---</p>	1,2,5-8
A	<p>PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05, 30 May 1997 (1997-05-30) & JP 09 002957 A (MITSUBISHI CHEM CORP), 7 January 1997 (1997-01-07) abstract</p> <p>---</p>	1-8
A	<p>PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05, 30 May 1997 (1997-05-30) & JP 09 002956 A (MITSUBISHI CHEM CORP), 7 January 1997 (1997-01-07) abstract</p> <p>---</p>	1-8
A	<p>WO 98 02450 A (INFLAZYME PHARMACEUTICALS LTD) 22 January 1998 (1998-01-22) example 25 page 178, line 9 - line 10 claims 27,29</p> <p>---</p>	1-8
A	<p>EP 0 659 762 A (MITSUBISHI CHEM CORP) 28 June 1995 (1995-06-28) page 108, line 23 - line 36 claims 1,3,27</p> <p>---</p>	1-8
A	<p>INOUE K ET AL: "Cholesterol induces apoptosis of cerebellar neuronal cells." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 5 MAR 1999, vol. 256, no. 1, 5 March 1999 (1999-03-05), pages 198-203, XP001188107 ISSN: 0006-291X the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-8

INTERNATIONAL SEARCH REPORT

PCT/GB 1380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KYOUNG SOOK KIM, ET AL.: "Effects of cholestanol feeding on corneal dystrophy in mice." BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1085, 1991, pages 343-349, XP008027217 the whole document	1-8
X	EP 0 162 330 A (ROECAR HOLDINGS NV) 27 November 1985 (1985-11-27) page 5, paragraph 2 - paragraph 3 claim 3	1,2,4-8
E	WO 03 077869 A (SAMARITAN PHARMACEUTICALS INC ;UNIV GEORGETOWN (US)) 25 September 2003 (2003-09-25) figure 1 page 5, line 14 - line 21 claims 1-8,10-14	1,2,4-8

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-8 relate to a large number of undefined compounds in terms of "derivative" (claims 1-8) and "prodrug" (1-3 and 5-8). In fact, the claims contain so many options that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Furthermore, present claim 1-7 relate to the treatment of a disease which actually is not well defined.

The use of the definition "non-cognitive neurodegeneration", "non-cognitive neuromuscular degeneration" or "motor-sensory neurodegeneration" or "receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is not fully possible to determine the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search over the whole scope of the claims impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely the use of the compounds according to formula (I), (II), (IV) and sapogenins and saponins in relation to the treatment of diseases as specifically mentioned in claim 8.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-2 (partially), 3, 4-8 (partially)

The use of compounds according to formula (I) and (Ia) for the manufacture of a medicament for the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment. The use of said compounds as active ingredients present in foodstuffs, food supplement and beverages.

2. Claims: 1-2 (partially) and 5-8 (partially)

The use of compounds according to formula (II) for the manufacture of a medicament for the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment. The use of said compounds as active ingredients present in foodstuffs, food supplement and beverages.

3. Claims: 1-2 (partially) and 5-8 (partially)

The use of compounds according to formula (III) for the manufacture of a medicament for the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment. The use of said compounds as active ingredients present in foodstuffs, food supplement and beverages.

4. Claims: 1-2 (partially) and 4-8 (partially).

The use of sapogenin derivatives bearing at least one X radical substituent wherein X is chosen from an halo atom, (Me-S-), (Me-SO-), (Me-SO₂-), N₃-, Nh₂-, Me-SO₂-NH-, and alkyl (i.e. compounds according to D. of claim 1) for the manufacture of a medicament for the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment, as far as not comprised by subjects 1 to 3. The use of said compounds as active ingredients present in foodstuffs, food supplement and beverages.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

INTERNATIONAL SEARCH REPORT

PCT/GB 21380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1024146	A	02-08-2000	CN 1212966 A 07-04-1999
		AU 9336098 A 23-04-1999	
		CA 2304770 A1 08-04-1999	
		EP 1024146 A1 02-08-2000	
		JP 2001518477 T 16-10-2001	
		US 6593301 B1 15-07-2003	
		WO 9916786 A1 08-04-1999	
WO 0149703	A	12-07-2001	AU 2386201 A 16-07-2001
		CA 2395100 A1 12-07-2001	
		CN 1452630 T 29-10-2003	
		EP 1246835 A2 09-10-2002	
		WO 0149703 A2 12-07-2001	
		JP 2003519624 T 24-06-2003	
		US 2003158161 A1 21-08-2003	
WO 9948507	A	30-09-1999	AU 748138 B2 30-05-2002
		AU 3157499 A 18-10-1999	
		AU 3158199 A 18-10-1999	
		BR 9909109 A 12-12-2000	
		BR 9909110 A 12-12-2000	
		CA 2325633 A1 30-09-1999	
		CA 2325634 A1 30-09-1999	
		CN 1302208 T 04-07-2001	
		CN 1301166 T 27-06-2001	
		EP 1066042 A2 10-01-2001	
		EP 1066033 A1 10-01-2001	
		WO 9948507 A2 30-09-1999	
		WO 9948482 A2 30-09-1999	
		GB 2335599 A , B 29-09-1999	
		HR 20000637 A1 30-04-2001	
		HR 20000638 A1 30-04-2001	
		HU 0101693 A2 28-12-2001	
		HU 0103654 A2 28-02-2002	
		ID 26989 A 22-02-2001	
		ID 26781 A 08-02-2001	
		JP 2003524581 T 19-08-2003	
		JP 2002507572 T 12-03-2002	
		NO 20004803 A 27-11-2000	
		NO 20004804 A 09-11-2000	
		PL 343423 A1 13-08-2001	
		PL 343508 A1 27-08-2001	
		TR 200002773 T2 21-11-2001	
		TR 200002774 T2 21-06-2001	
		US 2002193317 A1 19-12-2002	
		US 2003118673 A1 26-06-2003	
		ZA 200006046 A 28-01-2002	
		ZA 200006047 A 28-01-2002	
		GB 2347676 A 13-09-2000	
		US 2003032604 A1 13-02-2003	
		US 6258386 B1 10-07-2001	
		US 2001043955 A1 22-11-2001	
WO 0123406	A	05-04-2001	AU 7537500 A 30-04-2001
		BR 0014381 A 25-06-2002	
		CA 2385402 A1 05-04-2001	
		CN 1377368 T 30-10-2002	
		EP 1224205 A1 24-07-2002	

INTERNATIONAL SEARCH REPORT

PCT/GB 1380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0123406 A		WO 0123406 A1 HR 20020255 A1 JP 2003510332 T NO 20021541 A TR 200200821 T2 US 2003004147 A1 ZA 200202382 A	05-04-2001 31-08-2003 18-03-2003 28-05-2002 21-06-2002 02-01-2003 25-06-2003
WO 0123408 A	05-04-2001	AU 7538700 A BR 0014372 A CA 2385440 A1 CN 1377366 T EP 1224207 A1 WO 0123408 A1 JP 2003525869 T US 2003100542 A1	30-04-2001 25-06-2002 05-04-2001 30-10-2002 24-07-2002 05-04-2001 02-09-2003 29-05-2003
DE 4303214 A	11-08-1994	DE 4303214 A1	11-08-1994
US 4680289 A	14-07-1987	EP 0204661 A2 JP 61293915 A	10-12-1986 24-12-1986
JP 5246866 A	24-09-1993	NONE	
WO 0123407 A	05-04-2001	AU 7538200 A BR 0014355 A CA 2385410 A1 CN 1377367 T EP 1224206 A1 WO 0123407 A1 JP 2003510333 T US 2002183294 A1	30-04-2001 16-07-2002 05-04-2001 30-10-2002 24-07-2002 05-04-2001 18-03-2003 05-12-2002
JP 2002030096 A	29-01-2002	NONE	
JP 09002957 6 A		NONE	
JP 09002956 6 A		NONE	
WO 9802450 A	22-01-1998	AT 229031 T AU 722815 B2 AU 3332397 A BR 9710353 A CA 2259981 A1 WO 9802450 A2 DE 69717633 D1 DE 69717633 T2 EP 1304333 A2 EP 0917534 A2 ES 2187788 T3 JP 2001503732 T KR 2000023661 A NZ 333731 A RU 2196143 C2 US 6046185 A	15-12-2002 10-08-2000 09-02-1998 11-01-2000 22-01-1998 22-01-1998 16-01-2003 02-10-2003 23-04-2003 26-05-1999 16-06-2003 21-03-2001 25-04-2000 29-09-2000 10-01-2003 04-04-2000
EP 0659762 A	28-06-1995	AT 164587 T CA 2138839 A1	15-04-1998 25-06-1995

INTERNATIONAL SEARCH REPORT

PCT/GB 01380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0659762 A		CN 1108260 A ,B	13-09-1995
		DE 69409338 D1	07-05-1998
		DE 69409338 T2	03-09-1998
		DK 659762 T3	19-10-1998
		EP 0659762 A2	28-06-1995
		ES 2115856 T3	01-07-1998
		JP 7228592 A	29-08-1995
		TW 479061 B	11-03-2002
		US 5712254 A	27-01-1998
		US 5783564 A	21-07-1998
EP 0162330 A	27-11-1985	DE 3416112 A1	31-10-1985
		AT 86492 T	15-03-1993
		DE 3587160 D1	15-04-1993
		DE 3587160 T2	30-09-1993
		EP 0162330 A1	27-11-1985
WO 03077869 A	25-09-2003	WO 03077869 A2	25-09-2003